Clinical Trial Update: Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of two doses of an MF59C.1-adjuvanted monovalent H5N1 influenza vaccine in adults and elderly across four dos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• Monovalent Inactivated Influenza Vaccine with MF59C.1 (H5N1) (Monovalent MF59-adjuvanted H5N1 influenza vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pre-pandemic Influenza Vaccine | Phase 3 | Status: COMPLETED